Most of the professionals who find their way to a clinician specializing in ADHD have already tried a lot of things. Multiple medications. Multiple therapists. Multiple frameworks. They’ve been told they have anxiety, or depression, or both. They’ve been given prescriptions that helped — partially, temporarily, or not at all — and then adjusted, and adjusted again.
By the time they reach someone like Joyce Kinyua, they’re not looking for another medication suggestion. They’re looking for an explanation.
Joyce is a psychiatric nurse practitioner who has spent the last two years specializing in precision psychiatry — a clinical approach that goes deeper than symptom management and medication matching to ask a more fundamental question: why is this person’s brain and body operating the way it is, at the molecular level?
I sat down with her to talk about what that looks like in practice, what genetic testing is actually revealing about ADHD, and what it means when you can finally show a patient — in biological detail — that what they’re experiencing was never their fault.
What precision psychiatry actually is — and how it differs from what most people have encountered.
Most people who have heard of genetic testing in mental health are familiar with pharmacogenomic tests like GeneSight — tools that analyze how quickly the liver metabolizes certain medications, and produce a list of which drugs are likely to work better or worse for a given person’s genetic profile. Useful, but narrow.
What Joyce uses through Intellect DNA is a different kind of tool. It’s looking at single nucleotide polymorphisms — small variations in DNA — that affect not just how medications are processed, but how the body produces, absorbs, and utilizes the raw materials the brain needs to function. Micronutrients. Methylation pathways. Gut-brain signaling. Inflammatory markers. Detox pathways.
The result is a pyramid, as Joyce describes it. At the base: are you getting the right nutrients? Are you absorbing them? Are they actually reaching the brain? Moving up: what are the methylation pathways doing? What are the inflammatory markers showing? What’s happening in the detox pathways? Each layer builds on the one below, and addressing the base can sometimes produce changes that medication alone couldn’t.
The B12 case that changed everything.
Joyce shared a case that illustrates the impact of ADHD genetic testing in ways that a standard clinical interview can’t capture.
A woman in her mid-40s, newly diagnosed with ADHD, who had tried Adderall a decade earlier and remembered it helping. Joyce prescribed Adderall again — 20mg extended release, with a 10mg booster in the afternoon. The patient was stable. She was functioning. But she was operating at about 80% of her potential, and that gap wasn’t closing.
The ADHD genetic testing came back. Three significant findings: a methylation pathway variant (MTHFR) affecting her ability to convert folic acid into its active form, a related methylation gene (MTRR) compounding that difficulty, and a gene that was causing her to metabolize B12 extremely rapidly — meaning she was perpetually depleted despite anything she ate.
Joyce prescribed a compounded injection: methyl B12 with choline, inositol, and a compound addressing a detox pathway variant. Within two weeks, the patient called. She said she’d never been able to get through her to-do list the way she could now. Her spouse noticed. And perhaps most tellingly: she said the Adderall wasn’t even making the same difference it had been. The foundational nutritional piece had been the limiting factor the whole time.
A month later, at a follow-up appointment, the patient cried. She said: “I wonder how my life would have been if we had identified this earlier.”
Why labels help — and where they stop.
This is a conversation Joyce and I found ourselves having naturally, and it’s one worth unpacking.
Psychiatric diagnoses exist for reasons that are sometimes forgotten: to enable research by clustering groups of people with similar presentations, and to create a documented basis for insurance coverage and accommodation. Without the ADHD label, many of the patients Joyce and I both see wouldn’t have access to the services they need.
And the label does something else — something that’s harder to quantify but deeply important. For the high-achieving professional who has spent decades powering through, wondering why everything costs so much more effort than it seems to for everyone else, hearing “this is a recognized neurological pattern with a name” produces relief that no amount of reframing can replicate.
But the label is a category, not an explanation. It tells you what cluster of symptoms you fit, not why your specific brain works the way it does. What Joyce’s approach adds is the why — identifying the specific biological pathways that are contributing to the symptom picture, and targeting interventions at those pathways rather than at the symptoms alone.
The two approaches aren’t in competition. They’re different lenses on the same person.
What ADHD genetic testing can do practically for professionals who feel stuck.
Joyce’s observation is one I share from a different angle: by the time most people reach a specialist, they’ve been through the traditional system enough to know its limits. They’ve had the medication adjustments. They’ve done the therapy. They’ve tried the productivity systems and the coaching and the lifestyle changes.
What Joyce adds to the toolkit is the molecular layer — the piece that traditional psychiatry often doesn’t have time to investigate. And what the Intellect DNA results show, repeatedly, is that a significant number of people with ADHD symptoms are also dealing with nutrient deficiencies, methylation pathway variants, or absorption issues that standard blood panels miss.
Addressing those fundamentals doesn’t replace medication for everyone. But it can dramatically change what medication needs to do — and sometimes reveals that the medication was working less effectively than it should have been not because the prescription was wrong, but because the biological substrate wasn’t adequately supported.
The question that will shape the next decade of psychiatric care.
Joyce put it plainly at the end of our conversation: we no longer have to keep guessing what’s going on in the body. The tools exist. The question is whether the clinical system will move fast enough to use them.
For professionals with ADHD who have been in the “we’ve tried everything” category — this conversation is relevant. The goal isn’t to abandon what’s working. It’s to understand your body and your brain at a level of specificity that makes every other intervention more effective.
And for those who can’t yet access genetic testing: the foundational piece still matters. Adequate protein. Sleep taken seriously as a mood stabilizer and cognitive essential. Fruits, vegetables, fiber. Basic nutritional support that costs nothing beyond attention and time.
The future Joyce is describing is already here. The question is getting access to it.
If you’re a professional looking for a thorough ADHD assessment and treatment, Constellation PLLC serves patients across 25 states with a three-month intensive as our most popular offering. Reach out via the contact form at constellationpllc.com.
For precision psychiatry and genetic testing, Joyce Kinyua is licensed in Tennessee and Massachusetts and offers a free 15-minute consultation at info@mynuruhealth.com or 423-565-0235.
📌 Grab your copy of ADHD in Professionals: Embrace Your Brain here.
📌 Joyce Kinyua — Nuru Health: mynuruhealth.com
📌 Constellation PLLC: constellationpllc.com

